Blueprint Medicines Overview
- Year Founded
-
2008

- Status
-
Public
- Employees
-
649

- Stock Symbol
-
BPMC

- Investments
-
2
- Share Price
-
$93.94
- (As of Friday Closing)
Blueprint Medicines General Information
Description
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.
Contact Information
Website
www.blueprintmedicines.comCorporate Office
- 45 Sidney Street
- Cambridge, MA 02139
- United States
Corporate Office
- 45 Sidney Street
- Cambridge, MA 02139
- United States
Blueprint Medicines Stock Performance
As of 14-Feb-2025, Blueprint Medicines’s stock price is $93.94. Its current market cap is $6B with 63.9M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$93.94 | $95.19 | $80.42 - $121.90 | $6B | 63.9M | 832K | -$1.07 |
Blueprint Medicines Financials Summary
As of 31-Dec-2024, Blueprint Medicines has a trailing 12-month revenue of $509M.
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
---|---|---|---|---|
EV | 5,278,047 | 5,278,047 | 5,228,290 | 1,728,175 |
Revenue | 508,824 | 508,824 | 249,380 | 204,036 |
EBITDA | (21,421) | (21,421) | (475,558) | (523,779) |
Net Income | (67,089) | (67,089) | (506,984) | (557,517) |
Total Assets | 1,179,813 | 1,179,813 | 1,049,250 | 1,349,902 |
Total Debt | 469,106 | 469,106 | 332,497 | 242,451 |
Blueprint Medicines Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Blueprint Medicines Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Blueprint Medicines Comparisons
Industry
Financing
Details
Blueprint Medicines Competitors (92)
One of Blueprint Medicines’s 92 competitors is Allakos, a Formerly VC-backed company based in San Carlos, CA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Allakos | Formerly VC-backed | San Carlos, CA | ||||
Arcus Biosciences | Formerly VC-backed | Hayward, CA | ||||
AB Science | Formerly Accelerator/Incubator backed | Paris, France | ||||
Nektar Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom |
Blueprint Medicines Patents
Blueprint Medicines Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20240382493-A1 | Methods for treating systemic mastocytosis and gastrointestinal stromal tumors | Pending | 18-May-2023 | ||
US-20240262826-A1 | Wild type kit inhibitors | Pending | 30-Nov-2022 | ||
AU-2023265064-A1 | Salt and crystal forms of an epidermal growth factor receptor inhibitor | Pending | 04-May-2022 | ||
AU-2023255386-A1 | Kit inhibitors | Pending | 19-Apr-2022 | ||
AU-2023250382-A1 | Egfr inhibitors | Pending | 05-Apr-2022 | C07D401/14 |
Blueprint Medicines Signals
Blueprint Medicines Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Blueprint Medicines Investments & Acquisitions (2)
Blueprint Medicines’s most recent deal was a Early Stage VC with IDRx for . The deal was made on 28-Apr-2022.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
IDRx | 28-Apr-2022 | Early Stage VC | Drug Discovery | ||
Lengo Therapeutics | 30-Dec-2021 | Merger/Acquisition | Drug Discovery |
Blueprint Medicines ESG
Risk Overview
Risk Rating
Updated December, 21, 2023
22.33 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile

Pharmaceuticals
Industry
of 853
Rank
Percentile

Biotechnology
Subindustry
of 368
Rank
Percentile

Affiliates
Subsidiaries (1)
Name | Industry | Location | Year Founded |
---|---|---|---|
Blueprint Medicines (US Rights of Gavreto) |
Blueprint Medicines FAQs
-
When was Blueprint Medicines founded?
Blueprint Medicines was founded in 2008.
-
Where is Blueprint Medicines headquartered?
Blueprint Medicines is headquartered in Cambridge, MA.
-
What is the size of Blueprint Medicines?
Blueprint Medicines has 649 total employees.
-
What industry is Blueprint Medicines in?
Blueprint Medicines’s primary industry is Drug Discovery.
-
Is Blueprint Medicines a private or public company?
Blueprint Medicines is a Public company.
-
What is Blueprint Medicines’s stock symbol?
The ticker symbol for Blueprint Medicines is BPMC.
-
What is the current stock price of Blueprint Medicines?
As of 14-Feb-2025 the stock price of Blueprint Medicines is $93.94.
-
What is the current market cap of Blueprint Medicines?
The current market capitalization of Blueprint Medicines is $6B.
-
What is Blueprint Medicines’s current revenue?
The trailing twelve month revenue for Blueprint Medicines is $509M.
-
Who are Blueprint Medicines’s competitors?
Allakos, Arcus Biosciences, AB Science, Nektar Therapeutics, and Adaptimmune Therapeutics are some of the 92 competitors of Blueprint Medicines.
-
What is Blueprint Medicines’s annual earnings per share (EPS)?
Blueprint Medicines’s EPS for 12 months was -$1.07.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »